Sustaining Malaria Control in the Era of Artemisinin Partial Resistance and Expanding Vaccine Deployment
Abstract:
Malaria remains a leading cause of infectious disease morbidity and mortality, particularly in sub-Saharan Africa, where Plasmodium falciparum drives most severe disease and deaths. Despite major reductions in global burden over the past two decades, progress has plateaued due to persistent transmission, fragile health systems, and the rapid evolution of drug-resistant parasite strains. Artemisinin-based combination therapies continue to serve as first-line treatment in most endemic regions, yet partial artemisinin resistance linked to kelch13 mutations and growing partner drug resistance threatens their long term efficacy. At the same time, vaccine development has entered a new phase with the deployment of RTS,S and R21, which provide moderate protection but do not confer sterilizing or durable immunity. This review examines current antimalarial therapies, molecular mechanisms underlying resistance, emerging drug candidates, and next-generation vaccine strategies. It also evaluates how genomic surveillance, evolutionary dynamics, and integrated control approaches can shape future policy. Sustained innovation in pharmacology and immunology, coupled with strategic deployment and real-time resistance monitoring, will determine whether global malaria control advances or stagnates in the coming decades.
Introduction:
Malaria is a vector borne parasitic disease caused by protozoa of the genus Plasmodium and transmitted by female Anopheles mosquitoes. Among the five species infecting humans, Plasmodium falciparum accounts for the majority of severe cases, cerebral malaria, and mortality. The parasite’s complex life cycle, which spans mosquito and human hosts and includes liver and blood stages, complicates both therapeutic and vaccine strategies. Each developmental stage presents distinct biological vulnerabilities, yet also enables immune evasion and adaptation under selective pressure.
Over the last half century, malaria control has relied heavily on chemotherapeutic intervention. The introduction of chloroquine, followed by sulfadoxine pyrimethamine and later artemisinin based combination therapies, dramatically reduced case fatality rates. However, nearly every antimalarial deployed at scale has eventually encountered resistance. Genetic plasticity, high parasite replication rates, and widespread drug exposure create ideal conditions for adaptive evolution. Resistance is not static but dynamic, shaped by regional transmission intensity, drug use patterns, and parasite population structure.
Simultaneously, vaccine development has long represented a central goal in malaria research. Early efforts were hindered by antigenic diversity and incomplete understanding of protective immunity. The recent approval and rollout of RTS,S and R21 mark important milestones, yet these vaccines offer only partial and time limited protection. As drug resistance expands and elimination efforts intensify, understanding how pharmacologic and immunologic tools interact becomes increasingly important. A comprehensive evaluation of treatment efficacy, resistance mechanisms, vaccine performance, and future innovation is essential to inform sustainable malaria control strategies.
Current Antimalarial Treatments:
1. Artemisinin Based Combination Therapies (ACTs)
Artemisinin derivatives form the backbone of modern malaria treatment. Artemisinin based combination therapies combine a fast acting artemisinin derivative with a longer acting partner drug. This strategy reduces parasite biomass rapidly and lowers the probability that resistant parasites survive initial treatment.
Artemisinins are activated by heme iron within the parasite digestive vacuole, generating reactive intermediates that damage essential proteins and membranes. Their rapid parasite clearance rate distinguishes them from earlier drugs. In clinical settings, ACTs can reduce parasite density by several orders of magnitude within a single asexual replication cycle.
However, delayed parasite clearance has emerged in Southeast Asia and parts of East Africa. Mutations in the kelch13 gene correlate strongly with partial artemisinin resistance. These mutations alter parasite stress response pathways and reduce susceptibility during the ring stage. While artemisinin resistance alone does not always cause treatment failure, it increases the survival window during which partner drug resistance can develop.
2. Partner Drug Resistance
Resistance to ACT partner drugs now represents a central threat to treatment durability. Mutations in pfcrt and pfmdr1 influence susceptibility to chloroquine, amodiaquine, lumefantrine, and mefloquine. Amplification of plasmepsin 2 and 3 genes is associated with piperaquine resistance.
When parasites harbor both kelch13 mutations and partner drug resistance markers, treatment failure rates rise sharply. Surveillance studies demonstrate declining susceptibility to certain partner drugs in specific regions, signaling that ACT efficacy cannot be assumed stable. This has prompted investigation of triple ACT regimens designed to protect individual drugs through layered mechanisms of action.
3. Emerging Drug Candidates
Next-generation antimalarials target pathways distinct from classical heme detoxification. PfATP4 inhibitors disrupt parasite sodium homeostasis, leading to rapid parasite clearance even in strains resistant to older drugs. Dihydroorotate dehydrogenase inhibitors block pyrimidine biosynthesis, targeting an essential metabolic pathway. Translation elongation factor 2 inhibitors interfere with protein synthesis.
These agents aim to reduce cross-resistance with existing therapies. Their long term success will depend on rational deployment in combination regimens, strong pharmacovigilance systems, and integration with genomic monitoring to detect early resistance signals.
Molecular Mechanisms of Drug Resistance:
1. Genetic Determinants
Drug resistance in Plasmodium falciparum arises through point mutations, gene amplifications, and copy number variations. Key loci include kelch13, pfcrt, pfmdr1, and plasmepsin genes. Whole genome sequencing has revealed selective sweeps around these loci in regions with intense drug pressure, reflecting strong evolutionary selection.
Genomic surveillance platforms now enable near real time tracking of resistance markers. Portable sequencing technologies and targeted panels allow field based monitoring, improving responsiveness of national treatment guidelines.
2. Fitness Costs and Compensatory Evolution
Resistance mutations often impose fitness costs in drug free environments. However, compensatory mutations can restore parasite fitness while maintaining resistance phenotypes. This evolutionary flexibility complicates strategies that rely on drug withdrawal to restore susceptibility. Historical patterns, such as partial reemergence of chloroquine sensitivity in some areas after policy change, illustrate that outcomes vary depending on local evolutionary dynamics.
3. Transmission Intensity and Evolutionary Dynamics
Transmission intensity shapes resistance spread; In high transmission settings, multiple parasite clones may compete within a host, slowing fixation of resistant strains. In low transmission regions with heavy drug pressure, resistant lineages can expand rapidly. These dynamics highlight the need for region specific treatment policies informed by local epidemiology and genetic data.
Vaccine Development:
1. Pre Erythrocytic Vaccines
RTS,S and R21 target the circumsporozoite protein expressed on sporozoites. These vaccines aim to block infection at the liver stage before blood stage replication occurs. Clinical trials show moderate efficacy against clinical malaria in young children, with protection that wanes over time. Booster doses improve short-term protection but do not achieve sterilizing immunity.
Genetic diversity in circumsporozoite protein sequences may influence regional vaccine performance. Ongoing studies evaluate durability, optimal dosing schedules, and integration into existing immunization programs.
2. Blood Stage Vaccines
Blood stage vaccines target merozoite antigens involved in erythrocyte invasion. PfRH5 is a leading candidate due to its conserved structure and essential role in invasion. Preclinical studies demonstrate promising antibody responses, but achieving sustained high titers in humans remains challenging.
3. Transmission Blocking Vaccines
Transmission blocking vaccines focus on sexual stage antigens such as Pfs25. These vaccines aim to reduce parasite development within mosquitoes rather than directly protect vaccinated individuals. High coverage could reduce community level transmission and complement therapeutic and vector control interventions.
4. Integration of Therapeutics and Immunization
Combining partially effective vaccines with robust treatment strategies may produce synergistic reductions in transmission. Vaccines can lower parasite density and infection rates, while effective drug regimens clear symptomatic infections and reduce gametocyte carriage. Modeling studies suggest that even moderate vaccine efficacy can significantly reduce incidence when paired with strong case management and surveillance systems.
Future Directions:
Future priorities include development of multi target drug combinations, long acting injectable formulations, and mRNA based multistage vaccines. Integration of genomic surveillance into routine public health practice will allow early detection of resistance alleles and rapid policy adjustment. Host directed therapies and immune modulation strategies represent additional areas of exploration.
Conclusion
The trajectory of malaria control will depend on the balance between biomedical innovation and parasite adaptation. Artemisinin based combination therapies remain effective in most settings, but the documented spread of kelch13 mediated partial resistance and emerging partner drug failures demonstrate that current regimens cannot be assumed durable. Novel drug candidates that target previously unexploited parasite pathways offer renewed optimism, yet their long term success will require careful stewardship, combination strategies, and early detection of resistance markers.
Vaccines introduce an additional layer of protection by reducing infection incidence and disease severity. While current formulations such as RTS,S and R21 provide moderate efficacy, advances in antigen design, adjuvant optimization, and platform technologies such as mRNA may enable broader and more durable immunity. Importantly, integrating vaccines with effective treatment, vector control, and genomic surveillance could reduce transmission intensity and slow the evolutionary spread of resistance.
Malaria elimination will not be achieved through a single breakthrough. It will require coordinated application of multi stage vaccines, next generation therapeutics, real time molecular monitoring, and region specific policy adaptation. Continued investment in mechanistic research, evolutionary modeling, and implementation science will be essential. The capacity to anticipate and counter resistance, rather than respond after widespread treatment failure, will ultimately define the next era of global malaria control.
Sources:
Abdullah, S., et al. (2022). Safety and immunogenicity of the R21 malaria vaccine with Matrix M adjuvant in children in Burkina Faso. The Lancet Infectious Diseases, 22(3), 1–12. https://pmc.ncbi.nlm.nih.gov/articles/PMC9578402/
Ashley, E. A., Phyo, A. P., & Woodrow, C. J. (2018). Artemisinin resistance in Plasmodium falciparum. New England Journal of Medicine, 379(13), 1246–1257. https://pubmed.ncbi.nlm.nih.gov/28923866/
Balikagala, B., Fukuda, N., Ikeda, M., Katuro, O. T., Tachibana, S. I., Yamauchi, M., Opio, W., Emoto, S., Anywar, D. A., Kimura, E., et al. (2021). Evidence of artemisinin resistant malaria in Africa. New England Journal of Medicine, 385(13), 1163–1171. https://pubmed.ncbi.nlm.nih.gov/31375467/
Dondorp, A. M., Fairhurst, R. M., Slutsker, L., MacArthur, J. R., Breman, J. G., Guerin, P. J., Wellems, T. E., Ringwald, P., Newman, R. D., & Plowe, C. V. (2011). The threat of artemisinin resistant malaria. New England Journal of Medicine, 365(12), 1073–1075.
Kreutzfeld, O., Tumwebaze, P. K., Okitwi, M., Orena, S., Byaruhanga, O., Katairo, T., Conrad, M. D., Rasmussen, S. A., Legac, J., Aydemir, O., Giesbrecht, D., Forte, B., Campbell, P., Smith, A., Kano, H., Nsobya, S. L., Blasco, B., Duffey, M., Bailey, J. A., Cooper, R. A., … Rosenthal, P. J. (2023). Susceptibility of Ugandan Plasmodium falciparum isolates to the antimalarial drug pipeline. Microbiology Spectrum, 11(3), e0523622. https://doi.org/10.1128/spectrum.05236-22
Laurens, M. B. (2020). The promise of a malaria vaccine. Current Opinion in Immunology, 65, 1–7. https://pubmed.ncbi.nlm.nih.gov/36228916/
Nature Communications. (2024). Genomic surveillance of antimalarial drug resistance in Plasmodium falciparum. Nature Communications, 15, Article 45688. https://www.nature.com/articles/s41467-024-45688-z
Nguyen, T. D., Zupko, R. J., Conrad, M. D., Rukundo, G. B., Farinha, C. C., Asua, V. D., Tran, K. T., Grace, D. M., Rosenthal, P. J., Agaba, B. B., Kamya, M. R., Opigo, J., & Boni, M. F. (2025). Slowing the spread of treatment failure to artemisinin based combination therapies in Uganda. medRxiv: The Preprint Server for Health Sciences, 2025.05.15.25327701. https://doi.org/10.1101/2025.05.15.25327701
Okitwi, M., Orena, S., Tumwebaze, P. K., Katairo, T., Taremwa, Y., Byaruhanga, O., Tukwasibwe, S., Nsobya, S. L., Legac, J., Bailey, J. A., Cooper, R. A., Conrad, M. D., & Rosenthal, P. J. (2025). Changes in susceptibility of Plasmodium falciparum to antimalarial drugs in Uganda over time: 2019–2024. Nature Communications, 16(1), 7353. https://doi.org/10.1038/s41467-025-62810-x
Phillips, M. A., Burrows, J. N., Manyando, C., van Huijsduijnen, R. H., Van Voorhis, W. C., & Wells, T. N. C. (2017). Malaria. Nature Reviews Disease Primers, 3, 17050. https://pmc.ncbi.nlm.nih.gov/articles/PMC5016978/
Rosenthal, P. J., Asua, V., & Conrad, M. D. (2024). Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa. Nature Reviews Microbiology, 22(6), 373–384. https://doi.org/10.1038/s41579-024-01008-2
Rosenthal, P. J., Asua, V., Bailey, J. A., Conrad, M. D., Ishengoma, D. S., Kamya, M. R., Rasmussen, C., Tadesse, F. G., Uwimana, A., & Fidock, D. A. (2024). The emergence of artemisinin partial resistance in Africa: How do we respond? The Lancet Infectious Diseases, 24(9), e591–e600. https://doi.org/10.1016/S1473-3099(24)00141-5
RTS,S Clinical Trials Partnership. (2015). Efficacy and safety of RTS,S malaria vaccine with AS01 adjuvant in African children. The Lancet, 386(9988), 31–45.
World Health Organization. (2023). World malaria report 2023. World Health Organization. https://pmc.ncbi.nlm.nih.gov/articles/PMC102